SINOPHARM (01099) Schedules 20 Mar 2026 Board Meeting to Approve FY2025 Results and Dividend Proposal

Bulletin Express

03/10

Sinopharm Group Co. Ltd. (stock code: 01099) has announced that its board of directors will convene on 20 March 2026 to review and approve the consolidated financial results for the twelve months ended 31 December 2025. The meeting agenda also includes consideration of a dividend declaration.

The announcement, signed by Chairman Jin Bin and dated 10 March 2026, confirms that deliberations will cover the performance of the parent company and its subsidiaries for FY2025.

The current board composition comprises: • Executive directors: Lian Wanyong and Yang Binghua • Non-executive directors: Jin Bin, Chen Qiyu, Zu Jing, Xing Yonggang, Ma Yue, Chen Yuqing, Wen Deyong, and Li Ying • Independent non-executive directors: Li Peiyu, Wu Tak Lung, Yu Weifeng, Shi Shenghao, and Chen Weiru

Investors will receive Sinopharm’s audited annual results and any dividend decision following the 20 March 2026 board session.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1135632537"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1135632537\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1135632537?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135632537","market":"hk","top_or_hot":-1,"title":"SINOPHARM (01099) Schedules 20 Mar 2026 Board Meeting to Approve FY2025 Results and Dividend Proposal","media":"Bulletin Express","content":"<p>Sinopharm Group Co. Ltd. (stock code: 01099) has announced that its board of directors will convene on 20 March 2026 to review and approve the consolidated financial results for the twelve months ended 31 December 2025. The meeting agenda also includes consideration of a dividend declaration.</p>\n<p>The announcement, signed by Chairman Jin Bin and dated 10 March 2026, confirms that deliberations will cover the performance of the parent company and its subsidiaries for FY2025.</p>\n<p>The current board composition comprises:\n• Executive directors: Lian Wanyong and Yang Binghua  \n• Non-executive directors: Jin Bin, Chen Qiyu, Zu Jing, Xing Yonggang, Ma Yue, Chen Yuqing, Wen Deyong, and Li Ying  \n• Independent non-executive directors: Li Peiyu, Wu Tak Lung, Yu Weifeng, Shi Shenghao, and Chen Weiru</p>\n<p>Investors will receive Sinopharm’s audited annual results and any dividend decision following the 20 March 2026 board session.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SINOPHARM (01099) Schedules 20 Mar 2026 Board Meeting to Approve FY2025 Results and Dividend Proposal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSINOPHARM (01099) Schedules 20 Mar 2026 Board Meeting to Approve FY2025 Results and Dividend Proposal\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-10 16:43</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Sinopharm Group Co. Ltd. (stock code: 01099) has announced that its board of directors will convene on 20 March 2026 to review and approve the consolidated financial results for the twelve months ended 31 December 2025. The meeting agenda also includes consideration of a dividend declaration.</p>\n<p>The announcement, signed by Chairman Jin Bin and dated 10 March 2026, confirms that deliberations will cover the performance of the parent company and its subsidiaries for FY2025.</p>\n<p>The current board composition comprises:\n• Executive directors: Lian Wanyong and Yang Binghua  \n• Non-executive directors: Jin Bin, Chen Qiyu, Zu Jing, Xing Yonggang, Ma Yue, Chen Yuqing, Wen Deyong, and Li Ying  \n• Independent non-executive directors: Li Peiyu, Wu Tak Lung, Yu Weifeng, Shi Shenghao, and Chen Weiru</p>\n<p>Investors will receive Sinopharm’s audited annual results and any dividend decision following the 20 March 2026 board session.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01099","symbol_name":"國藥控股","start_time":0,"source_url":"","article_id":"1135632537","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135632537","pubTimestamp":1773132215,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sinopharm Group Co. Ltd. (stock code: 01099) has announced that its board of directors will convene on 20 March 2026 to review and approve the consolidated financial results for the twelve months...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01099":"国药控股"},"translate_title":"国药控股(01099)定于2026年3月20日召开董事会批准2025财年业绩及股息建议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":1},"content_text":"Sinopharm Group Co. Ltd. (stock code: 01099) has announced that its board of directors will convene on 20 March 2026 to review and approve the consolidated financial results for the twelve months ended 31 December 2025. The meeting agenda also includes consideration of a dividend declaration.\nThe announcement, signed by Chairman Jin Bin and dated 10 March 2026, confirms that deliberations will cover the performance of the parent company and its subsidiaries for FY2025.\nThe current board composition comprises:\n• Executive directors: Lian Wanyong and Yang Binghua  \n• Non-executive directors: Jin Bin, Chen Qiyu, Zu Jing, Xing Yonggang, Ma Yue, Chen Yuqing, Wen Deyong, and Li Ying  \n• Independent non-executive directors: Li Peiyu, Wu Tak Lung, Yu Weifeng, Shi Shenghao, and Chen Weiru\nInvestors will receive Sinopharm’s audited annual results and any dividend decision following the 20 March 2026 board session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}